Recent popular reports from Yimaike ★ GC019F CAR-T developed by Genxi Bio based on the FasTCAR platform for adult patients with relapsed
Cinda Bio/Reindeer Medical's BCMA CAR-T cell therapy was recognized as a breakthrough therapeutic drug
Time of Update: 2021-03-24
and transmembrane, 4-1BB costimulation and CD3ζ activation domains. The press release pointed out that based on rigorous screening and comprehensive in vitro and in vivo functional evaluation, IBI326 has
Heyuan Bio 2021 3rd Scientific Advisory Committee Cell Therapy Symposium was successfully held, all
Time of Update: 2021-02-10
the breakthrough achievements made by Heyuan Bio in the past year, and unanimously recommended that Heyuan Bio-High Quality and High Efficiency promote the clinical research process for the registration of the core product CNCT19 cell injections, while making
CD30 CAR-T Cell Therapy! Singapore Tesha Bio-Innovative Therapy is eligible for EU Priority Drug (PRIME): Treatment of Lymphoma (cHL)!
Time of Update: 2021-01-26
recently announced that the European Medicines Agency (EMA) has granted its CD30 directed self-embedded antigen-treated antigen-treated T-cell (CD30 CAR-T) therapy priority drug qualification (PRIME) for the treatment of recurring or refractic classic Hodgkin's lymphoma (R/R cHL).
Ruishun Bio: The first allogeneic DNT cell drug in China to treat relapsed acute myeloid leukemia has been approved clinically
Time of Update: 2021-01-22
. are targeted at tumor cells, consider how to kill tumors. And the role of immunotherapy drugs is to restore the normal function of the patient's immune cells as the core, through the "normalized" body immune system to kill cancer cells in the blood
Quantitative Cryo-Analytical Scanning Electron Microscopy (CEDX): An Important Technique Useful for Cell-Specific Localization of Salt
Time of Update: 2020-11-06
Advances in the techniques required for the X-ray microanalysis of cryo-fixed, naturally hydrated plant tissues in the cryo-scanning electron microscope have reached the stage that accurate, cell-specific localization and quantification
First-line immunotherapy for lung cancer! Cinda Bio/Lilly Daboshu ® treatment of non-scaly non
Time of Update: 2020-09-11
treatment of squamous non-small cell lung cancer (NSCLC) with the drug ® (Gisithamin) and platinum. is also the second ® NSCLC new adaptation application from Dabershu. , NMPA officially accepted the sNDA for non-scaly NSCLC ® treatment on April
Bio-skincare brand IMCELL I love cells ® technology, safety, effect.
Time of Update: 2020-08-30
collapsed and wrinkled - a process that can take months of continuous use. I think I love cell ® safe? Are there any side effects? "Because skin cells absorb different ingredients or factors with different effects, adding too many or insufficient
First-line immunotherapy for lung cancer! Synda Bio/Lilly Daberschu ® treatment of non-squamous non-small cell lung cancer Phase III clinical success!
Time of Update: 2020-08-27
ORIENT-11 is a randomized, double-blind, Phase III controlled clinical study that compared Daberschu ®or placebo combined force bitai® and platinum for advanced or recurrent non-scaly NSCLC first-line therapy without EGFR-sensitive mutations or ALK gene rearring.
Bio-carbon-containing single-cell quantitative techniques based on Raman group.
Time of Update: 2020-08-19
for Biofuels. determine the content of starch, triglycerides, and proteins in cells usually require s3 parallel processes, each consisting of complex steps such as cell culture to accumulate sufficient biomass, extract and isolate target compounds
New pretreatment of blood tumor targeted therapy? New Sharp Bio has received $110 million to push hematopoietic stem cells into clinical medicine.
Time of Update: 2020-07-17
Vor says its core technology, Engineered Hematopoietic Stem Cells (eHSC), has strong potential to expand the range of targeted blood tumor therapies and avoid therapeutic adverse events caused by the killing of healthy cells by therapeutic molecules.
Cinda Bio and Roche work closely to discover and develop multiple cell therapies and bispecific antibody products
Time of Update: 2020-06-26
today announced that it has entered into a strategic research and development partnership with Roche to identify and develop multiple products, including tumor cell therapy and bispecific antibodies.
NAT CELL BIO: Li's team develops an efficient cytosine editor
Time of Update: 2020-06-24
in addition, hyeA3A-BE4max selectively catalyzes cytoside conversion in TC base pairs, with a wider editing range and higher activity (up to 257 times).
CAR-T Cell Therapy and Bispecific Antibody Resustomino: Roche signs $2 billion partnership agreement with Cinda Bio
Time of Update: 2020-06-16
Roche's 2:1 T-cell bispecific antibodies (Image: Roche) Under the terms of the agreement, Sunda Bio, based in Suzhou, China, will pay upfront costs for the use of Roche's technology, as well as development, commercial milestone payments and royalties.
Kozy Bio CT053 Whole human anti-BCMA car car T cell injection obtained FDA approval
Time of Update: 2020-06-09
this approval is also the first time that China's original research CAR-T project in the United States independent lying for IND, and successfully obtained FDA approval.
FDA grants Corchi bio-whole BCMA CAR-T cell (CT053) "orphan drug" qualification
Time of Update: 2020-06-08
Orphan drugs are drug ( and biological products used to treat, diagnose, or prevent rare diseases/diseases that affect less than 200,000 people, and are granted by the US FDA Orphan Drug Product Development Office.
Cinda Bio publishes the results of phase 3 double-blind phase 3 of IBI305 treatment for advanced non-squamous non-small cell lung cancer
Time of Update: 2020-06-08
recently, cinda Bio Pharmaceutical s ( ( announced the results of the study of the effectiveness and safety of IBI305 (bevalbea mono-antibiotic
New auxiliary treatment approved for patients with stage IIIA non-small cell lung cancer approved by Junshi Bio Treplymono
Time of Update: 2020-06-07
Recently, according to relevant news, Junshi bio-Treplymono-approved clinical, for combined chemotherapy in the resectionable phase IIIA non-small cell lung cancer patients of the new auxiliary treatment. About
NAT CELL BIO: Liver cell aging secretions promote tumor development
Time of Update: 2020-06-05
further evidence by researchers that FBP1-defective liver cells promote HSC activation by releasing HMGB1.
Nat Cell Bio: Mysterious protein found in patients with advanced breast cancer that could be used to treat breast cancer
Time of Update: 2020-05-29
Introduction: The cause of breast cancer is not yet clear, early breast cancer often does not have typical symptoms and signs, not easy to attract attention, but the incidence of breast cancer is the first in women's malignant